Comparative Pharmacology
Head-to-head clinical analysis: POLYMOX versus UTIMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLYMOX versus UTIMOX.
POLYMOX vs UTIMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity, leading to cell lysis.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamases, preventing hydrolysis of amoxicillin.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; maximum 4 g/day.
For UTIMOX (amoxicillin/clavulanate), typical adult dose is 875 mg/125 mg orally every 12 hours or 500 mg/125 mg orally every 8 hours, depending on infection severity.
None Documented
None Documented
Terminal elimination half-life = 1-1.5 hours in adults; prolonged in renal impairment (up to 12-20 hours in anuria)
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 8-12 hours in severe impairment (CrCl <30 mL/min).
Renal (70-80% unchanged via tubular secretion and glomerular filtration); biliary/fecal (small amount, <5%)
Primarily renal (85-90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic